Heatwurx’s (PCSA) Sell (E+) Rating Reaffirmed at Weiss Ratings

Heatwurx (NASDAQ:PCSA)‘s stock had its “sell (e+)” rating reissued by equities research analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

Several other equities research analysts also recently issued reports on the company. HC Wainwright lowered their price target on Heatwurx from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, September 2nd. Zacks Research cut shares of Heatwurx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $1.00.

Heatwurx Trading Up 1.2%

Shares of NASDAQ PCSA opened at $0.31 on Friday. The company has a market cap of $15.62 million, a PE ratio of -0.13 and a beta of 1.53. Heatwurx has a 12-month low of $0.15 and a 12-month high of $1.50. The stock has a 50 day simple moving average of $0.25 and a 200-day simple moving average of $0.25.

Heatwurx (NASDAQ:PCSA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Sell-side analysts forecast that Heatwurx will post -4.05 earnings per share for the current fiscal year.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.